RT Journal Article
SR Electronic
T1 Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.15.20175489
DO 10.1101/2020.08.15.20175489
A1 Della Ventura, Bartolomeo
A1 Cennamo, Michele
A1 Minopoli, Antonio
A1 Campanile, Raffaele
A1 Bolletti Censi, Sergio
A1 Terracciano, Daniela
A1 Portella, Giuseppe
A1 Velotta, Raffaele
YR 2020
UL http://medrxiv.org/content/early/2020/08/18/2020.08.15.20175489.abstract
AB Mass testing is fundamental to face the pandemic caused by the coronavirus SARS-CoV-2 discovered at the end of 2019. To this aim, it is necessary to establish reliable, fast and cheap tools to detect viral particles in biological material so to identify the people capable to spread the infection. We demonstrate that a colorimetric biosensor based on gold nanoparticle (AuNP) interaction induced by SARS-CoV-2 lends itself as an outstanding tool for detecting viral particles in nasal and throat swabs. The extinction spectrum of a colloidal solution of multiple viral-target gold nanoparticles – AuNPs functionalized with antibodies targeting three surface proteins of SARS-CoV-2 (spike, envelope and membrane) – is redshifted in few minutes when mixed to a solution containing the viral particle. The optical density of the mixed solution measured at 560 nm was compared to the threshold cycle (Ct) of a Real Time-PCR (gold standard for detecting the presence of viruses) finding that the colorimetric method is able to detect very low viral load with a detection limit approaching that of RT-PCR. Since the method is sensitive to the infecting viral particle rather than to its RNA, the achievements reported here open new perspective not only in the context of the current and possible future pandemics, but also in microbiology as the biosensor proves itself to be a powerful though simple tool for measuring the viral particle concentration.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe consumables were partly purchased by Cosvitec scarlAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the IRB of the University of Naples Federico II with the document n. 140/20.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available upon request to the corresponding authors